Effects of selective estrogen receptor modulators and genistein on the expression of ERα/β and COX-1/2 in ovarectomized mouse uteri

This study was performed to examine the effects of selective estrogen receptor modulators [tamoxifen (TAM) and toremifene (TOR)] and pure anti-estrogen, ICI-182780 (ICI, Faslodex) and soybean isoflavone, genistein (GE) on the expression of estrogen-stimulated c-fos/jun, ERalpha/beta and COX-1/2 in the uteri of ovarectomized mice. TAM, TOR, ICI and GE treatment significantly decreased the levels of estradiol (E2)-induced c-fos. ICI and GE treatment significantly decreased the levels of E2-induced c-jun and ERalpha expressions. High doses of TOR treatment significantly increased the E2-induced ERbeta expression. In contrast, ICI and GE treatment significantly decreased the levels of E,-induced COX-2 expression, thus suggesting that TOR and GE might prevent E2-related endometrial carcinogenesis.

SERMs; Genistein; c-fos/jun; ERα/β; COX-1/2

[1] Flototto T., Djahasouzi S., Glaser M., Hanstein B., Niederacher D., Brumm C. et al.: "Hormones and hormone antagosists: mech­anisms of action in carcinogenesis of endometrial and breast cancer". Hor. Metab. Res., 2001, 33, 451.

[2] Chlebowski R.T., Col N., Winer E.P., Collyar D.E., Cummings S.R., Vogel VG. 3''et al.: "American Society of Clinical Oncol­ogy technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition". J. Clin. Oneal., 2002, 20, 3328.

[3] Bartsch H., Phillips D.H., Nair J., Hewer A., Meyberg-Solomeyer G., Grischke E.M.: "Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients" Carcinogenesis, 2000, 21, 845.

[4] Niwa K., Morishita S., Hashimoto M., Itoh T., Fujimoto J., Mon H. et al.: "Effects of tamoxifen on endometrial carcinogenesis in mice". Jpn. J. Cancer Res., 1998, 89, 502.

[5] Niwa K., Hashimoto M., Lian Z., Gao J., Tagami K., Yokoyama Y et al.: "Inh伽tory effects of toremifene on N-methyl-N-nitrosourea and estradiol-17β－induced endometrial carcinogenesis in mice" Jpn. J. Cancer Res., 2002, 93, 626.

[6] Adamson E.D.: "Oncogenes in development". Development, 1987, 99, 449.

[7] Weitz A., Bresciania F.: "Estrogen induces expression of c-fos and c- myc protooncogenes in the rat uterus". Mol. Endocrinol., 1988, 2,816.

[8] Weitz A., Cicatiell L., Persiot E., Scalona M., Bresciani F.: "Estro­gen stimulation of transcription of c-jun protooncogene". Mol Endocrinol., 1990, 4, 1031.

[9] Morishta S., Niwa K., lchigo S., Hori M., Murase T., Fujimoto J et al.: "Overexpression of c-fos/jun mRNA and their oncoprotein (Fos/Jun) in the mouse uterus treated with three natural estro­gens". Cancer Lett., l 995, 97, 225.

[10] Niwa K., Hashimoto M., Morishita S., Yokoyama Y., Mori H., Tanaka T. et al.: "Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice". Jpn. J. Cancer Res., 1993, 84, 951.

[11] Gstafsson J.A.: "Estrogen receptor β- A new dimension in estro­gen mechanism of action". J. Endocrinol., 1999, 163, 379.

[12] Taylor A.H., AI-Azzawi F.: "Immunolocalisation of oestrogen receptor beta in human tissues". J. Mo!. Endocrinol., 2000, 24, 145.

[13] Kuiper G.G.J.M., Lemmen J.G., Carlsson L.B., Corton J.C., Safe S.H., van der Saag P.T. et al.: "Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor W'. Endocrinology, 1998, 139, 4252.

[14] Bardin A., Boulle N., Lazennec G., Vignon F., Pujor P.: "Loss of ERβ expression as a common step in estrogen-dependent tumor progression". Endocr. Re/at. Cancer, 2004, JI, 537.

[15] Lazennec G.: "Estrogen receptor beta, a possible tumor suppres­sor involved in ovarian carcinogenesis". Cancer Lett., 2006, 231, 151.

[16] Ferrandina G., Legge F., Ranelletti F.O., Zannoni G.F., Maggiano N., Evangelist A. et al.: "Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic para­meters and clinical outcome". Cancer, 2002, 95, 801.

[17] Jabbour H.N., Milne S.A., Williams A.R., Anderson R.A., Boddy S.C.: "Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors". Br. J. Cancer, 2001, 85, 1023.

[ 18] Tagami K., Niwa K., Lian Z., Gao J., Mori H., Tamaya T.: "Pre­ventive effect of Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent". Biol. Pharm. Bull., 2004, 27, 156.

[ 19] Chomczynski P., Sacchi N. et al.: "Single-step method of RNA isolation by acid guanitdium thiocynate-phenol-chloroform cxtraction".Anal. Biochem., 1987, 162, 156.

[20] Hirai H., Momoeda M., Inoue S., Tsuchiya F., Mastumi H., Tsutumi 0. et al.: "Stage-specific expression of estrogen receptor subtypes and estrogen responsive finger protein in preimplanta­tional mouse embryos". Endoc,: J., 1999, 46, 153.

[21] Jang M., Pezzuto J.M.: "Effects of resveratrol on 12-0-tetrade­canoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin". Cancer Lett., 1998, 134, 81.

[22] Giri D.D., Dangerfield VJ., Lonsdale R., Rogers K., Underwood J.C.: "Immunohistology of oestrogen receptor and D5 antigen in breast cancer: correlation with oestrogen receptor content of adja- cent cryostat sections assayed by radioligand binding and enzyme immunoassay". J. Clin. Pathol., I 987, 40, 734.

[23] Goulding H., Pinder S., Cannon P., Pearson D., Nicholson R., Snead D. et al.: "A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples". Hum. Pathol., 1995, 26, 291.

[24] Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K. et al.: "Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers". Am. J. Pathol., 148, 1567.

[25] Fujiwaki R., Iida K., Kanasaki H., Ozaki T., Hata K., Miyazaki K "Cyclooxygenase-2 expression in endometrial cancer: correlation with rnicrovessel count and expression of vascular endothelial growth factor and thyrnmidine phosphorylase". Hum. Pathol., 2002, 33,213.

[26] Lian Z., Niwa K., Tagami K., Hashimoto M., Gao J., Yokoyama Y et al.: "Preventive effects of isoflavones, genistein and daidzein, on estradiol-17β-related endornetrial carcinogenesis in mice". Jpn. J. Cancer Res., 2001, 92, 726.

[27] Lian Z., Niwa K., Onogi K., Mori H., Harrigan R.C., Tamaya T "Anti-tumor effects of herbal medicines on endometrial carcino­mas via estrogen receptor-alpha-related mechanism". Oncol. Rep., 2006, 15, 1133.